Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets.
The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal.
Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing.
The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter.
The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal.
Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.
